Abstract:Abstract Abstract 4014 The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic stem/progenitor cells. Although demethylating agents such azacytidine and decitabine have been widely used to treat MDS, the underlying molecular mechanisms remain obscure. Abnormalities of microRNAs (miRNA) have been recently associated with hematological malignancies including MDS. The miR-124 was initially demonstrated to modulate neurogenesis. It was recently shown that EVI1-induced methylation and silencing of miR-124 were present in murine MDS cells. In the retrospective study we evaluated methylation status and expression levels of miR-124 in fifteen MDS patients (subtypes included RCUD, RCMD, RAEB-1, RAEB-2 and CMML). Genomic DNA samples were modified with bisulfite and methylation at three promoter regions of miR-124 was examined with methylation-specific real time quantitative polymerase chain reaction analysis (MQPCR). In general, we observed an increased methylation levels of miR-124 in MDS patients than that in normal bone marrow (NBM, P<0.01). In accordance with this, marked depression of miR-124 was seen in six patients when compared with NBM (more than 2 times lower), as determined with quantitative reverse-transcriptive PCR assay. Moreover, there were higher degrees of promoter methylation in cases with depressed miR-124 than that in remaining cases. A negative correlation between the expression and methylation levels was statistically significant (R= -0.498, P<0.01). The change of miR-124 was not directly related to short-term clinical response or prognosis, possibly due to limited size of the sample. However, the miR-124 amount returned to basal levels in two cases (RCMD and CMML subtypes respectively) after low-dose decitabine therapy and DNA methylation of all three loci disappeared. Continued work is underway to accumulate more cases and make long-term clinical follow-up. In conclusion, this primary work suggested a possible role of the methylation-mediated silencing of miR-124 in the pathogenesis or disease progression of MDS. Disclosures: No relevant conflicts of interest to declare.

Methylation by NSun2 represses the levels and function of microRNA 125b.

MicroRNA Mediates DNA Methylation of Target Genes.

Overexpression of Nsun2 by Dna Hypomethylation is Associated with Metastatic Progression in Human Breast Cancer

Suppression of SUN2 by DNA methylation is associated with HSCs activation and hepatic fibrosis

MicroRNA-125b Promotes Neuronal Differentiation in Human Cells by Repressing Multiple Targets

Mrna Methylation by Nsun2 in Cell Proliferation

3′-Terminal 2′-O-methylation of Lung Cancer Mir-21-5p Enhances Its Stability and Association with Argonaute 2

The tRNA methyltransferase NSun2 stabilizes p16INK4 mRNA by methylating the 3[prime]-untranslated region of p16

The Trna Methyltransferase NSun2 Stabilizes P16ink4 Mrna by Methylating the 3′-Untranslated Region of P16

Recent advances in methylation modifications of microRNA

Methylation As A Crucial Step in Plant Microrna Biogenesis

Distinct Roles of m5C RNA Methyltransferase NSUN2 in Major Gynecologic Cancers

Sirnas Compete with Mirnas for Methylation by HEN1 in Arabidopsis.

Distinct Roles of m<SUP>5</SUP>C RNA Methyltransferase NSUN2 in Major Gynecologic Cancers

Progress on the Relationship Between Mir-125 Family and Tumorigenesis

NSUN2-mediated RNA methylation: Molecular mechanisms and clinical relevance in cancer

Proteinase-activated Receptor 2 Promotes Cancer Cell Migration through RNA Methylation-mediated Repression of miR-125b

Sequence- and Structure-Selective Mrna M5c Methylation by NSUN6 in Animals

Promoter Methylation and Decreased Expression of Mir-124 in Myelodysplastic Syndromes

NSUN2-Mediated m5C Methylation and METTL3/METTL14-Mediated m6A Methylation Cooperatively Enhance p21 Translation.

Methylation Protects Mirnas and Sirnas from a 3′-End Uridylation Activity in Arabidopsis